Summary by Moomoo AI
On October 4, 2024, 180 Life Sciences Corp. announced it had regained compliance with Nasdaq's minimum shareholder equity requirement, following a decision by the Nasdaq Hearing Panel on July 1, 2024. The company will be monitored for one year to ensure ongoing compliance. However, 180 Life Sciences remains non-compliant with Nasdaq's audit committee requirements, specifically the need for at least three independent directors. The company has until the earlier of its next annual shareholders' meeting or May 7, 2025, to meet this requirement, with a deadline of November 4, 2024, if the shareholders' meeting occurs before that date. Failure to comply may lead to delisting, but the company is actively seeking qualified independent directors to regain compliance. Additionally, on October 9, 2024, 180 Life Sciences issued a press release about...Show More
